Ovarian Cancer
FDA approves mirvetuximab soravtansine-gynx for subset of women with ovarian cancer
The FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of certain adults with epithelial ovarian, fallopian tube or primary peritoneal cancer.
Black women less likely to receive guideline-concordant therapy for ovarian cancer
Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.
Ovarian Cancer Awareness Month: Studies show advances in treatment, symptom management
September is Ovarian Cancer Awareness Month.
Novel bispecific T-cell receptor therapy shows early promise in advanced solid tumors
An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.
Olaparib regimen extends survival for certain women with advanced ovarian cancer
Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.
Genetic counseling relatively low cost, ‘should be offered to more at-risk patients’
Submitted medical claims and out-of-pocket costs for genetic counseling encounters appeared relatively low among patients with certain cancer types, according to a research letter published in JAMA Health Forum.
Daily aspirin use may reduce ovarian cancer risk among high-risk patients
Women who take aspirin frequently may reduce their risk for ovarian cancer, according to results of a meta-analysis published in Journal of Clinical Oncology.
Gene therapy fails to significantly extend survival in ovarian cancer, topline data show
A phase 3 trial of ofranergene obadenovec in platinum-resistant ovarian cancer failed to meet its primary endpoints of statistically significant improvement in PFS and OS, according to topline data released by the agent’s manufacturer.
Novel approaches highlight potential of cell therapy for a wider array of cancers
The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.
Tool improves women’s ‘sense of control’ over ovarian cancer symptoms
Women with recurrent ovarian cancer experience an average of 14 disease or treatment-related symptoms at any given time over the course of their disease.